Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

62 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) compared with premix or addition of meal-time insulin to basal insulin in people with type 2 diabetes: A systematic review and Bayesian network meta-analysis.
Home P, Blonde L, Kalra S, Ji L, Guyot P, Brulle-Wohlhueter C, Murray E, Shah R, Sayre T, Shaunik A. Home P, et al. Among authors: guyot p. Diabetes Obes Metab. 2020 Nov;22(11):2179-2188. doi: 10.1111/dom.14148. Epub 2020 Sep 3. Diabetes Obes Metab. 2020. PMID: 32700442
Efficacy and safety of iGlarLixi versus IDegLira in adults with type 2 diabetes inadequately controlled by glucagon-like peptide-1 receptor agonists: a systematic literature review and indirect treatment comparison.
Home PD, Aroda VR, Blonde L, Guyot P, Shaunik A, Fazeli MS, Goswami H, Kalra S, Pourrahmat MM. Home PD, et al. Among authors: guyot p. Diabetes Obes Metab. 2020 Nov;22(11):2170-2178. doi: 10.1111/dom.14136. Epub 2020 Jul 26. Diabetes Obes Metab. 2020. PMID: 32627297
Gastrointestinal adverse events with insulin glargine/lixisenatide fixed-ratio combination versus glucagon-like peptide-1 receptor agonists in people with type 2 diabetes mellitus: A network meta-analysis.
Rayner CK, Wu T, Aroda VR, Whittington C, Kanters S, Guyot P, Shaunik A, Horowitz M. Rayner CK, et al. Among authors: guyot p. Diabetes Obes Metab. 2021 Jan;23(1):136-146. doi: 10.1111/dom.14202. Epub 2020 Oct 22. Diabetes Obes Metab. 2021. PMID: 32991041 Free PMC article.
Network meta-analysis of immune-oncology monotherapy as first-line treatment for advanced non-small-cell lung cancer in patients with PD-L1 expression ⩾50.
Freemantle N, Xu Y, Wilson FR, Guyot P, Chen CI, Keeping S, Konidaris G, Chan K, Kuznik A, Atsou K, Glowienka E, Pouliot JF, Gullo G, Rietschel P. Freemantle N, et al. Among authors: guyot p. Ther Adv Med Oncol. 2022 Jun 16;14:17588359221105024. doi: 10.1177/17588359221105024. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 35747163 Free PMC article.
Relative benefit-risk comparing diclofenac to other traditional non-steroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors in patients with osteoarthritis or rheumatoid arthritis: a network meta-analysis.
van Walsem A, Pandhi S, Nixon RM, Guyot P, Karabis A, Moore RA. van Walsem A, et al. Among authors: guyot p. Arthritis Res Ther. 2015 Mar 19;17(1):66. doi: 10.1186/s13075-015-0554-0. Arthritis Res Ther. 2015. PMID: 25879879 Free PMC article. Review.
62 results